

10081147

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:26:12 ON 25 NOV 2002

=> FIL REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:26:21 ON 25 NOV 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

~~COPYRIGHT (C) 2002 American Chemical Society (ACS)~~

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2002 HIGHEST RN 474353-54-3

DICTIONARY FILE UPDATES: 24 NOV 2002 HIGHEST RN 474353-54-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10081147.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

10081147

=> s l1 sss sam
SAMPLE SEARCH INITIATED 17:26:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 447 TO ITERATE

100.0% PROCESSED 447 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7672 TO 10208
PROJECTED ANSWERS: 55 TO 503

L2 14 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:26:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9236 TO ITERATE

100.0% PROCESSED 9236 ITERATIONS 340 ANSWERS
SEARCH TIME: 00.00.01

L3 340 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 140.28 140.49

FILE 'CAPLUS' ENTERED AT 17:26:49 ON 25 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2002 VOL 137 ISS 22
FILE LAST UPDATED: 24 Nov 2002 (20021124/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3 full
L4 10 L3


=> d l4 1-10 ibib abs hitstr

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS

10081147

ACCESSION NUMBER: 2002:793619 CAPLUS
 DOCUMENT NUMBER: 137:294870
 TITLE: Preparation of prodrugs of 3-(pyrrol-2-ylmethylidene)-
 2-indolinones and activity as modulators of protein
 kinases
 INVENTOR(S): Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho;
 Koenig, Marcel; Zhou, Yong; Vojkovsky, Tomas;
 Nematalla, Asaad S.
 PATENT ASSIGNEE(S): Sugan, Inc., USA
 SOURCE: PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081466	A1	20021017	WO 2002-US11001	20020409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-282630P P 20010409	
OTHER SOURCE(S):			MARPAT 137:294870	
GI				



I

AB The present invention relates to pyrrole substituted 2-indolinone compds.
 (shown as I; e.g. 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-
 oxo-2,3-dihydroindole-1-carbonyl chloride) and their pharmaceutically
 acceptable salts which modulate the activity of protein kinases and
 therefore are expected to be useful in the prevention and treatment of
 protein kinase related cellular disorders such as cancer (no data). In I,
 R1 and R2 are independently H, halo, alkyl, alkylthio, nitro,
 trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl,
 -C(O)R7 (R7 is alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy,
 heteroaryloxy, heterocycle, and aminoalkylamino), -NR8R9, -NR8C(O)R9,
 -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alkyl, aryl and
 heteroaryl, or R8 and R9 together with the N to which they are attached
 form a satd. heterocycloamino). R3 is H, alkyl, hydroxyalkyl, aminoalkyl,
 -C(O)R7, aryl, and heteroaryl; R4 is H, alkyl, -C(O)R7 aryl, and
 heteroaryl. R5 is H and -COR10 where R10 is alkyl, alkoxy, hydroxy, aryl,

aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR₁₁R₁₂ where R₁₁ is H or alkyl, and R₁₂ is aminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R₄ and R₅ together form - (CH₂)₄- or - (CH₂)_mCO(CH₂)_n- wherein n is 0 to 3, provided that n+m is 3. R₆ is: (c) -OR₁₃ wherein R₁₃ is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alkyl chain are optionally replaced by O, -NR₁₄- (R₁₄ is H or alkyl), -S-, or -SO₂-; or. (d) -NR₁₅R₁₆ where R₁₅ and R₁₆ are independently H, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alkyl chain are optionally replaced by O, -NR₁₇- (R₁₇ is H or alkyl), -S-, or -SO₂-; or R₁₅ and R₁₆ together with the N atom to which they are attached form satd. or unsatd. heterocycloamino;. Although the methods of prepn. are not claimed, >80 example preps. are included, both of I and the unprotected version of I in which the C(O)R₆ group has been replaced by H.


IT **356068-94-5P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 356068-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **326914-13-0P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


10081147

(Preparation); RACT (Reactant or reagent); USES (Uses)
(protein kinase modulator; prepn. of prodrugs of
(pyrrolylmethylidene)indolinones and activity as modulators of protein
kinases)

RN 326914-13-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-
dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



IT 342641-60-5P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid-(2-dimethylaminoethyl) amide
342641-61-6P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl) amide
342641-62-7P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl) amide
342641-63-8P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide
342641-64-9P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl) amide
342641-65-0P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl) amide
342641-66-1P, 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-dimethylaminoethyl) amide 342641-67-2P, 5-[6-(3-Methoxyphenyl)-
2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-
carboxylic acid (2-dimethylaminoethyl) amide 342641-68-3P,
2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide 342641-69-4P
, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl) amide
342641-70-7P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl) amide
342641-71-8P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide
342641-72-9P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-
yl)ethyl) amide 342641-73-0P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-
dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid
(3-(imidazol-1-yl)propyl) amide 342641-74-1P,
5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide
342641-75-2P, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-
dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl) amide 342641-76-3P, 2,4-Dimethyl-5-(2-oxo-6-
pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic
acid (2-(pyrrolidin-1-yl)ethyl) amide 342641-77-4P,
2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-
pyrrole-3-carboxylic acid (3-dimethylaminopropyl) amide
342641-78-5P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl) amide

342641-79-6P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
342641-80-9P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
342641-81-0P, 3-[4-(3-Diethylaminopropylcarbonyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)amide **342641-82-1P**,
 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-83-2P**,
 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-84-3P**
 , 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide **342641-85-4P**
 , 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide
342641-87-6P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide
342641-88-7P, 5-[6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-89-8P**,
 5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
342641-91-2P, 5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-92-3P**,
 5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
342641-93-4P, 5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-94-5P**,
 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **342641-95-6P**
 , 3-[4-(2-Diethylaminoethylcarbonyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
342641-96-7P, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342641-97-8P**,
 5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
342641-98-9P, 2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **342642-01-7P**,
 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
342642-02-8P, 5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **346405-32-1P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **356068-82-1P**,
 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
356068-90-1P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
356068-91-2P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
356068-92-3P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ethyl)amide
356068-95-6P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
356068-96-7P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
356068-97-8P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z))-


10081147

ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-ethylaminoethyl)amide **356068-99-0P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethyl-N-oxoaminoethyl)amide **356069-03-9P**,
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide
356069-04-0P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide **356069-05-1P**, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(4-methylpiperazin-1-yl)ethyl]amide **356069-07-3P**,
5-(2-Oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide
356069-09-5P, 5-(2-Oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide **356069-12-0P**, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl]amide **356069-13-1P**,
5-(5-Chloro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide
356069-15-3P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl]amide **468745-38-2P**,
5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-2-yl)ethyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase modulator; prepn. of prodrugs of
(pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 342641-60-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-61-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-62-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-63-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-64-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342641-65-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 342641-66-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



10081147


RN 342641-67-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 342641-68-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-69-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA


10081147

INDEX NAME)




RN 342641-71-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



10081147


RN 342641-73-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-74-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-75-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



10081147


RN 342641-76-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-77-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-78-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-79-6 CAPLUS


10081147

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-80-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-81-0 CAPLUS


CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


10081147



RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI)
(CA INDEX NAME)




RN 342641-84-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI)
(CA INDEX NAME)




RN 342641-85-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

10081147



RN 342641-87-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 342641-88-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-89-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxy-5-(1-methylethyl)phenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-91-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-92-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 342641-93-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-95-6 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-96-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-97-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-98-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-02-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 356068-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-90-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



10081147


RN 356068-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-92-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-95-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


10081147



RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356068-99-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 356069-03-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 356069-04-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 356069-05-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)

10081147




RN 356069-07-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-12-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 356069-13-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-15-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 468745-38-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10081147



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:658111 CAPLUS

DOCUMENT NUMBER: 137:185408

TITLE: 3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors

INVENTOR(S): Guan, Huiping; Liang, Congxin; Sun, Li; Tang, Peng
Cho; Wei, Chung Chen; Mauragis, Michael A.; Vojkovsky, Tomas; Jin, Qingwu; Herrinton, Paul Matthew

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066463	A1	20020829	WO 2002-US4407	20020215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-268683P	P 20010215
			US 2001-312361P	P 20010815

OTHER SOURCE(S): MARPAT 137:185408

GI



AB Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO₂H, (un)substituted NH₂, CONH₂; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH₂, SO₂NH₂, (un)esterified CO₂H, SO₂R₈, R₈ = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R₃-R₆ = H, alkyl; R₇ = H, alkyl, aryl, heteroaryl, acyl; Z = aryl, heteroaryl, heterocyclic, (un)substituted NH₂] were prepd. for use as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolicarboxylate was oxidized to the 5-carboxaldehyde, followed by ester hydrolysis, reaction with 5-fluoro-2-oxindole and amidation to give the amide II.

IT 375798-55-3P 452104-42-6P 452104-43-7P
 452104-44-8P 452104-45-9P 452104-46-0P
 452104-47-1P 452104-48-2P 452104-49-3P
 452104-50-6P 452104-62-0P 452104-63-1P
 452104-64-2P 452104-65-3P 452104-66-4P
 452104-67-5P 452104-68-6P 452104-69-7P
 452104-70-0P 452104-71-1P 452104-72-2P
 452104-73-3P 452104-74-4P 452104-75-5P
 452104-76-6P 452104-77-7P 452104-78-8P
 452104-79-9P 452104-80-2P 452104-81-3P
 452104-82-4P 452104-83-5P 452104-84-6P
 452104-85-7P 452104-86-8P 452104-87-9P
 452104-88-0P 452104-89-1P 452104-90-4P
 452104-91-5P 452104-92-6P 452105-04-3P
 452105-05-4P 452105-06-5P 452105-07-6P
 452105-08-7P 452105-09-8P 452105-10-1P
 452105-11-2P 452105-12-3P 452105-13-4P
 452105-14-5P 452105-15-6P 452105-16-7P
 452105-17-8P 452105-18-9P 452105-19-0P
 452105-20-3P 452105-21-4P 452105-22-5P
 452105-23-6P 452105-24-7P 452105-25-8P
 452105-26-9P 452105-27-0P 452105-28-1P
 452105-29-2P 452105-30-5P 452105-31-6P
 452105-32-7P 452105-44-1P 452105-45-2P
 452105-46-3P 452105-47-4P 452105-62-3P

10081147

452105-63-4P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)

RN 375798-55-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 452104-42-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 452104-43-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

10081147



RN 452104-44-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-45-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-46-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 452104-47-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-48-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-49-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 452104-50-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)




RN 452104-62-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

10081147



RN 452104-63-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-64-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-65-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-66-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-67-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-68-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-69-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-70-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-71-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-72-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-73-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-74-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-75-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-76-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 452104-77-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 452104-78-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)


10081147




RN 452104-79-9 CAPLUS



CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 452104-80-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 452104-81-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147

PAGE 1-A




PAGE 2-A




RN 452104-82-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147

PAGE 1-A




PAGE 2-A




RN 452104-83-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147

PAGE 1-A




PAGE 2-A




RN 452104-84-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147

PAGE 1-A




PAGE 2-A



RN 452104-85-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-86-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
 (CA INDEX NAME)

10081147


Double bond geometry as shown.



RN 452104-87-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 452104-88-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 452104-89-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147

RN 452104-90-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-91-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-92-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-04-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 452105-05-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-06-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-07-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-08-7 CAPLUS

10081147

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-09-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-10-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452105-11-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.


10081147



RN 452105-12-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452105-13-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-14-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10081147



RN 452105-15-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-16-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-17-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




10081147



RN 452105-18-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-19-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-20-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147

RN 452105-21-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-22-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 452105-24-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


10081147



RN 452105-25-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-26-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-27-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147



RN 452105-28-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-29-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 452105-30-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-

10081147

ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-
2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-31-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-
2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 452105-32-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A






RN 452105-44-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-45-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-46-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10081147



RN 452105-47-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-62-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-63-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10081147



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:539677 CAPLUS

DOCUMENT NUMBER: 137:109202

TITLE: Preparation of 4-aryl substituted indolinones as protein kinase signal transduction modulators for inhibiting abnormal cell proliferation

INVENTOR(S): Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu; Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li, Xiaoyuan; Wei, Chung-Chen; Tang, Peng Cho

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 560 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055517	A2	20020718	WO 2001-US48564	20011220
WO 2002055517	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-256479P P 20001220

OTHER SOURCE(S): MARPAT 137:109202

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepd. and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepd. via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I

10081147

were evaluated against eight specific kinases, e.g., FGFR1, for which I possessed IC50 values (.mu.M) of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.


IT 442558-05-6P 442558-07-8P 442558-08-9P
 442558-09-0P 442558-15-8P 442558-16-9P
 442558-17-0P 442558-23-8P 442558-24-9P
 442558-25-0P 442558-31-8P 442558-32-9P
 442558-33-0P 442558-39-6P 442558-40-9P
 442558-41-0P 442558-48-7P 442558-49-8P
 442558-50-1P 442558-54-5P 442558-56-7P
 442558-57-8P 442558-58-9P 442558-62-5P
 442558-63-6P 442558-65-8P 442558-66-9P
 442558-67-0P 442558-71-6P 442558-88-5P
 442558-89-6P 442558-90-9P 442558-91-0P
 442558-92-1P 442558-93-2P 442558-94-3P
 442558-96-5P 442558-97-6P 442558-98-7P
 442559-03-7P 442559-05-9P 442559-07-1P
 442559-08-2P 442559-09-3P 442559-14-0P
 442559-19-5P 442559-20-8P 442559-42-4P
 442559-43-5P 442559-53-7P 442559-54-8P
 442559-55-9P 442559-57-1P 442559-79-7P
 442559-80-0P 442559-97-9P 442559-98-0P
 442559-99-1P 442560-00-1P 442560-01-2P
 442560-02-3P 442560-03-4P 442560-04-5P
 442560-07-8P 442560-09-0P 442560-10-3P
 442560-11-4P 442560-14-7P 442560-22-7P
 442560-25-0P 442560-26-1P 442560-27-2P
 442560-29-4P 442560-39-6P 442560-43-2P
 442560-44-3P 442560-51-2P 442560-69-2P
 442560-79-4P 442560-80-7P 442560-81-8P
 442560-83-0P 442560-88-5P 442561-01-5P
 442561-06-0P 442561-07-1P 442561-11-7P
 442561-12-8P 442561-13-9P 442561-39-9P
 442561-48-0P 442561-52-6P 442561-53-7P
 442561-54-8P 442561-55-9P 442561-56-0P
 442561-76-4P 442561-77-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)

RN 442558-05-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-4-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-07-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 442558-08-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 442558-09-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 442558-15-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-16-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




10081147



RN 442558-17-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-23-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 442558-24-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 442558-25-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 442558-31-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-32-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 442558-33-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-39-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147



RN 442558-40-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 442558-41-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 442558-48-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442558-49-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




10081147




RN 442558-50-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl] (9CI) (CA INDEX NAME)




RN 442558-54-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




10081147




RN 442558-56-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-57-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-58-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 442558-62-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-63-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 442558-65-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


10081147

NAME)



RN 442558-66-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 442558-67-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 442558-71-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 442558-88-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-89-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

10081147




RN 442558-90-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-91-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-92-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

10081147




RN 442558-93-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-94-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 442558-96-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 442558-97-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 442558-98-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




10081147



RN 442559-03-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-05-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-07-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 442559-08-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 442559-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 442559-14-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-19-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 442559-20-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-
(9CI) (CA INDEX NAME)




CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 442559-53-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-((diethylamino)propyl)-5-[(Z)-[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI)
 (CA INDEX NAME)


Double bond geometry as shown.



RN 442559-54-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442559-55-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidiny)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 442559-57-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147

RN 442559-79-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442559-80-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-97-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442559-98-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-methyl-1-piperidiny)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442559-99-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10081147



RN 442560-00-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 442560-01-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-02-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442560-03-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-4-methyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-04-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442560-07-8 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-09-0 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-

10081147


indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 442560-10-3 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442560-11-4 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-14-7 CAPLUS

CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 442560-22-7 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147



RN 442560-25-0 CAPLUS
CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 442560-26-1 CAPLUS
CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-27-2 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442560-29-4 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-39-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(4-[1,1'-biphenyl]-3-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-43-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-44-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(4-[1,1'-biphenyl]-2-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442560-51-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-69-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-[3-[2-(dimethylamino)-2-oxoethyl]phenyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-79-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442560-80-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 442560-81-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147



RN 442560-83-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442560-88-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,4-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1-pyrrolidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442561-01-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 442561-06-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442561-07-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-11-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442561-12-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-13-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-39-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-

10081147

(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-48-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-52-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-[(methylamino)carbonyl]phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442561-53-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-54-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442561-55-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-56-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2-fluoro-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 442561-76-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 442561-77-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10081147



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:31440 CAPLUS

DOCUMENT NUMBER: 136:102386

TITLE: Preparation and use of 4-heteroaryl-3-heteroarylidényl-2-indolinones and their use as protein kinase inhibitors

INVENTOR(S): Tang, Peng-Cho; Wei, Chung-Chen; Huang, Ping; Cui, Jingron

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002551	A1	20020110	WO 2001-US20768	20010629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001070260	A5	20020114	AU 2001-70260	20010629
PRIORITY APPLN. INFO.:			US 2000-215654P	P 20000630
			WO 2001-US20768	W 20010629

OTHER SOURCE(S): MARPAT 136:102386

GI

10081147



AB Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, etc.; Het = (un)substituted arom. heterocycle contg. at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted arom. heterocycle contg. not more than two N atoms, 5-membered ring (un)substituted heterocycle contg. N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepd. Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis(pinacolato)diborane (DMSO, KOAc, PdCl2(dppf).bul.CH2Cl2, 80.degree.C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine.bul.HCl (THF, Pd(PPh3)4, NaOH, 70.degree.C, 6 h) to give the indole which was treated with C5H5N.bul.Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dihydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.


IT 388116-64-1P 388116-99-2P 388117-08-6P
388117-10-0P 388117-12-2P 388117-28-0P
388117-30-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; prepn. and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-64-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 388116-99-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 388117-08-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 388117-10-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 388117-12-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10081147




RN 388117-28-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 388117-30-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:868415 CAPLUS

DOCUMENT NUMBER: 136:697

TITLE: Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

10081147

INVENTOR(S): Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping;
Tang, Peng Cho
PATENT ASSIGNEE(S): Sugen, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090068	A2	20011129	WO 2001-US16757	20010524
WO 2001090068	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002032204	A1	20020314	US 2001-863804	20010524
US 2002035140	A1	20020321	US 2001-863905	20010524
US 6451838	B2	20020917		
US 2002037878	A1	20020328	US 2001-863819	20010524
US 6482848	B2	20021119		

PRIORITY APPLN. INFO.: US 2000-207000P P 20000524
US 2000-225045P P 20000811

OTHER SOURCE(S): MARPAT 136:697

AB The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. that modulate the activity of protein kinases ("PKs"). Pharmaceutical compns. comprising these compds., methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compns. comprising these compds. and methods of prepg. them are also disclosed.


IT 326914-13-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 326914-13-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 375798-55-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone

10081147

derivs.)
RN 375798-55-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:617993 CAPLUS

DOCUMENT NUMBER: 135:195497

TITLE: Preparation of pyrrole-substituted 2-indolinone
protein kinase inhibitors for treatment of cancer
INVENTOR(S): Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li;
Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin;
Vojkovsky, Tomas; Nematalla, Asaad S.

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060814	A2	20010823	WO 2001-US4813	20010215
WO 2001060814	A3	20020124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002156292	A1	20021024	US 2001-783264	20010215
EP 1255752	A2	20021113	EP 2001-914376	20010215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			


PRIORITY APPLN. INFO.:
US 2000-182710P P 20000215
US 2000-216422P P 20000706
US 2000-243532P P 20001027
WO 2001-US4813 W 20010215

OTHER SOURCE(S): MARPAT 135:195497

GI



I



II

AB The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, OH, alkoxy, acyl, (un)substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un)substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un)substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepd. as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFR.beta. and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 .mu.M. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.

IT 326914-13-0P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 326914-13-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10081147



IT 326914-09-4P 326914-10-7P 326914-17-4P
 326914-19-6P 342641-60-5P 342641-61-6P
 342641-62-7P 342641-63-8P 342641-64-9P
 342641-65-0P 342641-66-1P 342641-67-2P
 342641-68-3P 342641-69-4P 342641-70-7P
 342641-71-8P 342641-72-9P 342641-73-0P
 342641-74-1P 342641-75-2P 342641-76-3P
 342641-77-4P 342641-78-5P 342641-79-6P
 342641-80-9P 342641-81-0P 342641-82-1P
 342641-83-2P 342641-84-3P 342641-85-4P
 342641-87-6P 342641-88-7P 342641-89-8P
 342641-91-2P 342641-92-3P 342641-93-4P
 342641-94-5P 342641-95-6P 342641-96-7P
 342641-97-8P 342641-98-9P 342642-01-7P
 342642-02-8P 342642-09-5P 342642-10-8P
 342642-11-9P 346405-32-1P 356068-82-1P
 356068-90-1P 356068-91-2P 356068-92-3P
 356068-94-5P 356068-95-6P 356068-96-7P
 356068-97-8P 356068-99-0P 356069-03-9P
 356069-04-0P 356069-05-1P 356069-07-3P
 356069-09-5P 356069-12-0P 356069-13-1P
 356069-15-3P 356069-16-4P 356069-17-5P
 356069-18-6P 356069-19-7P 356069-20-0P
 356069-21-1P 356069-22-2P 356069-23-3P
 356069-24-4P 356069-25-5P 356069-26-6P
 356069-27-7P 356069-28-8P 356069-29-9P
 356069-30-2P 356069-31-3P 356069-33-5P
 356069-34-6P 356069-35-7P 356069-36-8P
 356069-37-9P 356069-38-0P 356069-39-1P
 356069-40-4P 356069-41-5P 356069-42-6P
 356069-43-7P 356069-44-8P 356069-45-9P
 356069-46-0P 356069-47-1P 356069-48-2P
 356069-49-3P 356069-50-6P 356069-51-7P
 356069-53-9P 356069-55-1P 356069-57-3P
 356069-58-4P 356069-59-5P 356069-60-8P
 356069-61-9P 356069-62-0P 356069-64-2P
 356069-65-3P 356069-66-4P 356069-67-5P
 356069-68-6P 356069-69-7P 356069-70-0P
 356069-71-1P 356069-72-2P 356069-73-3P
 356069-74-4P 356069-75-5P 356069-76-6P
 356069-77-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 326914-09-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 326914-10-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 326914-17-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 326914-19-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



10081147


RN 342641-60-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-61-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-62-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-63-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-64-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-65-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-66-1 CAPLUS


10081147

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 342641-67-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 342641-68-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-69-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342641-70-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-71-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-72-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-


10081147

ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-73-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-74-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-75-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-76-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-77-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-78-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-80-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



10081147


RN 342641-81-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-83-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 342641-84-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

10081147




RN 342641-85-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)



RN 342641-87-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA


10081147

INDEX NAME)



RN 342641-89-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


CCc1ccc(cc1)-c2ccc3c(c2)c(=O)[nH]3C=Cc4c(C)c(C)[nH]4C(=O)NCCCN5CCCC5

1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

10081147




RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-95-6 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-96-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-97-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-98-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-02-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-09-5 CAPLUS

CN Glycine, N-[[5-[[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


10081147



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 346405-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 356068-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356068-90-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



10081147


RN 356068-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-92-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 356068-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147




RN 356068-95-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356068-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356068-99-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-03-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 356069-04-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 356069-05-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 356069-07-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


10081147



RN 356069-09-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-12-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-13-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-15-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10081147




RN 356069-16-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-17-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 356069-18-6 CAPLUS


CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-82-1

CMF C22 H25 Cl N4 O2


10081147



CM 2

CRN 97-67-6
CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).



RN 356069-19-7 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5
CMF C22 H27 F N4 O2




CM 2

CRN 97-67-6
CMF C4 H6 O5

10081147

Absolute stereochemistry. Rotation (-).




RN 356069-20-0 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-90-1

CMF C22 H27 Cl N4 O2




CM 2

CRN 97-67-6

CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



RN 356069-21-1 CAPLUS


CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 346405-32-1

CMF C22 H25 F N4 O2


10081147



CM 2

CRN 97-67-6
CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).



RN 356069-22-2 CAPLUS
CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356069-16-4
CMF C20 H23 F N4 O2




CM 2

CRN 97-67-6
CMF C4 H6 O5

10081147

Absolute stereochemistry. Rotation (-).



RN 356069-23-3 CAPLUS


CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-99-0

CMF C22 H27 F N4 O3

Double bond geometry as shown.




CM 2

CRN 97-67-6

CMF C4 H6 O5


Absolute stereochemistry. Rotation (-).



RN 356069-24-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetilamino)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10081147

RN 356069-25-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-26-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-27-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-28-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-29-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-30-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-31-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-33-5 CAPLUS

10081147


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-32-4

CMF C22 H24 Br N5 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 356069-34-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-35-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-36-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-37-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-38-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-39-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




10081147

RN 356069-40-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-41-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 356069-42-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-43-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-44-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-45-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-46-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-47-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-48-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-49-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-50-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-51-7 CAPLUS

10081147

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-53-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8

CMF C22 H24 F N5 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 356069-55-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-,

10081147


mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-54-0

CMF C22 H25 N5 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 356069-57-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 356069-56-2

CMF C23 H24 N6 O3

Double bond geometry as shown.


10081147



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 356069-58-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-59-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-60-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-61-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 356069-62-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 356069-64-2 CAPLUS

10081147


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1

CMF C22 H24 Cl N5 O3


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 356069-65-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-66-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 356069-67-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-68-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-69-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 356069-70-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)

10081147


Double bond geometry as shown.



RN 356069-71-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 356069-72-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 356069-73-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-74-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-75-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10081147



RN 356069-76-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 356069-77-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10081147



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:472477 CAPLUS

DOCUMENT NUMBER: 135:56059

TITLE: Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds

INVENTOR(S): Lipson, Ken; McMahon, Gerald

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045689	A2	20010628	WO 2000-US35009	20001222
WO 2001045689	A3	20020103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002010203	A1	20020124	US 2000-741842	20001222
EP 1255536	A2	20021113	EP 2000-991704	20001222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 1999-171693P	P 19991222
			WO 2000-US35009	W 20001222

OTHER SOURCE(S): MARPAT 135:56059

AB The invention concerns indolinone compds. and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity of c-kit kinase.

IT 342641-94-5 346405-32-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indolinone derivs. for c-kit tyrosine protein kinase function modulation)

10081147


RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 346405-32-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:396655 CAPLUS

DOCUMENT NUMBER: 135:19549

TITLE: Preparation of pyrrole substituted 2-indolinones as antitumor agents

INVENTOR(S): Shenoy, Narmada; Sorasuchart, Waranush

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 249 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037820	A2	20010531	WO 2000-US32277	20001122
WO 2001037820	A3	20011213		

10081147

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1233943 A2 20020828 EP 2000-982228 20001122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


PRIORITY APPLN. INFO.:

US 1999-167544P A1 19991124

WO 2000-US32277 W 20001122

OTHER SOURCE(S): MARPAT 135:19549

GI



AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl, etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H, alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prepd. and formulated. E.g., a multi-step synthesis of I [R1-R7 = H; R8, R10 = Me; R9 = (CH2)2CO2H] which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addn. to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compd., are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.

IT 251356-61-3P 251356-63-5P 251356-64-6P
251356-65-7P 251356-66-8P 251356-67-9P
251356-68-0P 251356-69-1P 251356-70-4P
251356-71-5P 251356-72-6P 251356-73-7P
251356-74-8P 251356-75-9P 251356-76-0P
251356-77-1P 251356-78-2P 342641-60-5P
342641-61-6P 342641-62-7P 342641-63-8P
342641-64-9P 342641-65-0P 342641-66-1P
342641-67-2P 342641-68-3P 342641-69-4P
342641-70-7P 342641-71-8P 342641-72-9P


10081147

342641-73-0P 342641-74-1P 342641-75-2P
342641-76-3P 342641-77-4P 342641-78-5P
342641-79-6P 342641-80-9P 342641-81-0P
342641-82-1P 342641-83-2P 342641-84-3P
342641-85-4P 342641-87-6P 342641-88-7P
342641-89-8P 342641-91-2P 342641-92-3P
342641-93-4P 342641-94-5P 342641-95-6P
342641-96-7P 342641-97-8P 342641-98-9P
342642-01-7P 342642-02-8P 342642-09-5P
342642-10-8P 342642-11-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrole substituted 2-indolinones as antitumor agents)


RN 251356-61-3 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 251356-63-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-64-6 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 251356-65-7 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

10081147




RN 251356-66-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-68-0 CAPLUS


CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-69-1 CAPLUS


CN 2H-Indol-2-one, 6-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

10081147




RN 251356-70-4 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 251356-71-5 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 251356-72-6 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 251356-73-7 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

10081147




RN 251356-74-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 251356-75-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-76-0 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-77-1 CAPLUS


CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10081147




RN 251356-78-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)




RN 342641-60-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-61-6 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-62-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


10081147



RN 342641-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-65-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-66-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)



RN 342641-67-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)




RN 342641-68-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[[1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


10081147



RN 342641-69-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 342641-70-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-71-8 CAPLUS


10081147

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-72-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-73-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-74-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-75-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-76-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


10081147



RN 342641-77-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-78-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342641-79-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147




RN 342641-80-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-81-0 CAPLUS


CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-82-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-2,4-dimethyl-5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)

10081147




RN 342641-83-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI)
(CA INDEX NAME)



RN 342641-84-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI)
(CA INDEX NAME)




RN 342641-85-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

10081147




RN 342641-87-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 342641-88-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-89-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-91-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-92-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 342641-93-4 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342641-95-6 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 342641-96-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147



RN 342641-97-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 342641-98-9 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

10081147




RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 342642-02-8 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 342642-09-5 CAPLUS

CN Glycine, N-[[5-[[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


10081147



RN 342642-10-8 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342642-11-9 CAPLUS
CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:688215 CAPLUS
DOCUMENT NUMBER: 133:252306
TITLE: Preparation of indolinones as protein kinase inhibitors.
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Miller, Todd Anthony; Shirazian, Shahrzad; Wei, Chung Chen; Harris, G. Davis; Xiaoyuan, Li; Liang, Congxin
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


10081147

```

-----
WO 2000056709      A1      20000928      WO 2000-US7704      20000322
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
    CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
    ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
    LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
    SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
    ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
    DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
    CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1165513      A1      20020102      EP 2000-916622      20000322
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.:
                                US 1999-125945P  P  19990324
                                US 1999-127863P  P  19990405
                                US 1999-131192P  P  19990426
                                US 1999-132243P  P  19990503
                                WO 2000-US7704   W  20000322

OTHER SOURCE(S):      MARPAT 133:252306
GI

```



I


AB Title compds., e.g. [I; m, n = 0, 1; Q = (JR11)m; Q1 = (DR6)n; when n = 1, then A, B, D, E, F = C, N; .ltoreq.3 of A, B, D, E, F = N; when m = 1, then G, H, J, K, L = C, N; .gtoreq.1 and .ltoreq.3 of G, H, J, K, L = N; when n = 0, then A = C, N, B, F = C, N, NH, O, S; E = C, N, O, S; when m = 0, then G = C, N, H, K, l = C, N, NH, O, S; R1-R13 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, SH, alkylthiol, aryloxy, amino, etc.; R4R5 or R5R6 or R6R7 or R7R8 = atoms to form a 5-6 membered (hetero)aryl ring; with addnl. provisos], were prepd. Thus, 6-pyridin-3-yl-1,3-dihydroindol-2-one (prepn. given), 4-methoxy-3-thien-2-ylbenzaldehyde, and piperidine were refluxed overnight in EtOH to give 15% 3-(4-methoxy-3-thien-2-ylbenzylidene)-6-pyridin-3-yl-1,3-dihydroindol-2-one. Tested title compds. inhibited HER2 kinase with IC50 = 16.4 .mu.M to .gtoreq.100 .mu.M.

IT 251356-74-8P 295799-29-0P 295799-47-2P
295799-51-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolinones as protein kinase inhibitors)

RN 251356-74-8 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

10081147




RN 295799-29-0 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-[2-[3-(1-methylethyl)phenoxy]ethyl]- (9CI)
(CA INDEX NAME)




RN 295799-47-2 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 295799-51-8 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-thienyl)- (9CI) (CA INDEX NAME)




10081147




IT 251356-61-3P 251356-63-5P 251356-65-7P
251356-66-8P 251356-67-9P 251356-68-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of indolinones as protein kinase inhibitors)
RN 251356-61-3 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-63-5 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 251356-65-7 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 251356-66-8 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

10081147




RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-68-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:764021 CAPLUS

DOCUMENT NUMBER: 132:12257

TITLE: Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors

INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 240 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961422	A1	19991202	WO 1999-US12069	19990528
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				

10081147

TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314156	AA 19991202	CA 1999-2314156	19990528
AU 9944102	A1 19991213	AU 1999-44102	19990528
EP 1082305	A1 20010314	EP 1999-927120	19990528



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

BR 9910792	A 20020129	BR 1999-10792	19990528
US 6395734	B1 20020528	US 1999-322297	19990528
JP 2002516310	T2 20020604	JP 2000-550828	19990528
NO 2000005916	A 20010129	NO 2000-5916	20001122

PRIORITY APPLN. INFO.:

US 1998-87310P	P	19980529
US 1999-116106P	P	19990115
WO 1999-US12069	W	19990528

OTHER SOURCE(S): MARPAT 132:12257
 GI



AB The present invention relates to 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid derivs. (I) [where R1 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, aryl, OH, alkoxy, carboxy, acetyl, (thio)amido, (trihalomethane)sulfonyl, etc.; R2 = H, halo, (cyclo)alkyl, (hetero)aryl, or heteroalicyclic; R3, R4, R5, R6, R8, R9, R10 = independently H, (cyclo)alkyl, trihaloalkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heteroalicyclic, OH, alkoxy, SH, alkylthio, arylthio, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxy, amido, CN, NO2, halo, (thio)carbonyl, (un)substituted amino, etc.] which modulate the activity of protein kinases and are useful in the prevention and treatment of protein kinase related cellular disorders, such as cancer. Thus, 2,4-dimethyl-5-ethoxycarbonyl-3-(2-ethoxycarbonyl)pyrrole was deprotected using NaOH to form 3-(2-carboxyethyl)-2,4-dimethylpyrrole (100%) and the product C-5 formylated (two methods given for 86% and 90% yield, resp.). Reaction with 2-oxindole in EtOH and pyrrolidine or in aq. NaOH yielded II (88% and 91%, resp.), which reduced the av. size of C6 human glioma and melanoma tumors s.c. implanted in mice by 80-85%. II,

10081147

when administered orally, demonstrated notably superior efficacy compared to structurally similar analogs.


IT 251356-61-3P 251356-63-5P 251356-64-6P
251356-65-7P 251356-66-8P 251356-67-9P
251356-68-0P 251356-69-1P 251356-70-4P
251356-71-5P 251356-72-6P 251356-73-7P
251356-74-8P 251356-75-9P 251356-76-0P
251356-77-1P 251356-78-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid protein kinase inhibitors as antitumor agents)


RN 251356-61-3 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 251356-63-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-64-6 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 251356-65-7 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

10081147




RN 251356-66-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 251356-68-0 CAPLUS


CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 251356-69-1 CAPLUS


CN 2H-Indol-2-one, 6-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

10081147




RN 251356-70-4 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 251356-71-5 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 251356-72-6 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 251356-73-7 CAPLUS


CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

10081147




RN 251356-74-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 251356-75-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 251356-76-0 CAPLUS


CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 251356-77-1 CAPLUS

CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

10081147



RN 251356-78-2 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10081147

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER

NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.